Ambea AB (SE:AMBEA)
:AMBEA
Want to see SE:AMBEA full AI Analyst Report?
Top Page
Ambea AB
(AMBEA)
Select Model
Select Model
Rating:68Neutral
Price Target:
kr160.00
▲(15.69% Upside)
Action:ReiteratedDate:05/09/26
The score is driven primarily by solid operating performance and strong cash-flow conversion, tempered by elevated leverage that reduces financial flexibility. Technicals are a clear positive with the stock trending above key moving averages and supportive momentum. Valuation is broadly reasonable with a modest dividend yield.
Positive Factors
Recurring public-funded revenue model
Ambea’s core model is contract-driven and largely funded by municipalities and public agencies, yielding recurring, multi-year revenue streams. This provides durable demand visibility tied to demographic aging and limits reliance on one-off sales, supporting steady occupancy planning and workforce investment.
Negative Factors
Elevated leverage
Leverage is a structural constraint: debt-to-equity >2x and rising to ~2.6x TTM increases refinancing, interest-rate and covenant risk. High leverage reduces strategic flexibility for M&A, margin management, or shareholder returns and increases sensitivity to operating setbacks or policy changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring public-funded revenue model
Ambea’s core model is contract-driven and largely funded by municipalities and public agencies, yielding recurring, multi-year revenue streams. This provides durable demand visibility tied to demographic aging and limits reliance on one-off sales, supporting steady occupancy planning and workforce investment.
Read all positive factors
Ambea AB (AMBEA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr11.63B
Dividend Yield1.56%
Average Volume (3M)135.59K
Price to Earnings (P/E)16.4
Beta (1Y)0.56
Revenue Growth15.74%
EPS Growth15.67%
CountrySE
Employees38,000
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)8.55
Shares Outstanding84,101,290
10 Day Avg. Volume127,005
30 Day Avg. Volume135,589
Financial Highlights & Ratios
PEG Ratio1.73
Price to Book (P/B)2.27
Price to Sales (P/S)0.74
P/FCF Ratio5.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)10.91
Revenue Forecast (FY)kr17.27B
Ambea AB Business Overview & Revenue Model
Company Description
Ambea AB (publ) provides housing, support, education, and personnel for health and social care for the elderly and people with disabilities in Sweden, Norway, and Denmark. The company operates through Nytida, Vardaga, Stendi, Altiden, and Klara se...
How the Company Makes Money
Ambea makes money by operating care services and receiving compensation for delivering agreed volumes and quality levels of care. Its revenue model is predominantly service-based and recurring, with the largest revenue streams typically coming fro...
Ambea AB Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
48
Neutral
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.61B | 16.04B | 14.20B | 13.31B | 12.63B | 11.48B |
| Gross Profit | 8.83B | 2.81B | 2.44B | 3.44B | 12.19B | 11.06B |
| EBITDA | 3.00B | 2.71B | 2.61B | 2.28B | 2.04B | 1.61B |
| Net Income | 712.00M | 665.00M | 620.00M | 455.00M | 366.00M | 237.00M |
Balance Sheet | ||||||
| Total Assets | 20.98B | 20.48B | 18.48B | 17.89B | 17.88B | 16.67B |
| Cash, Cash Equivalents and Short-Term Investments | 173.00M | 133.00M | 28.00M | 6.00M | 259.00M | 86.00M |
| Total Debt | 13.36B | 12.64B | 11.05B | 10.74B | 10.96B | 9.89B |
| Total Liabilities | 15.81B | 15.28B | 13.49B | 12.97B | 13.19B | 12.14B |
| Stockholders Equity | 5.17B | 5.20B | 4.99B | 4.92B | 4.68B | 4.53B |
Cash Flow | ||||||
| Free Cash Flow | 1.96B | 2.03B | 1.95B | 1.62B | 1.33B | 1.11B |
| Operating Cash Flow | 2.10B | 2.17B | 2.07B | 1.71B | 1.44B | 1.21B |
| Investing Cash Flow | -1.43B | -1.39B | -358.00M | -93.00M | -214.00M | -258.00M |
| Financing Cash Flow | -518.00M | -672.00M | -1.69B | -1.88B | -1.04B | -882.00M |
Ambea AB Technical Analysis
Positive
138.30
Price Trends
130.90
Positive
133.47
Positive
129.45
Positive
Market Momentum
1.34
Negative
54.61
Neutral
37.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:AMBEA, the sentiment is Positive. The current price of 138.3 is above the 20-day moving average (MA) of 133.48, above the 50-day MA of 130.90, and above the 200-day MA of 129.45, indicating a bullish trend. The MACD of 1.34 indicates Negative momentum. The RSI at 54.61 is Neutral, neither overbought nor oversold. The STOCH value of 37.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:AMBEA.
Ambea AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | kr11.63B | 16.37 | 12.96% | 1.56% | 15.74% | 15.67% | |
64 Neutral | kr9.05B | 12.30 | 12.65% | 2.31% | 6.06% | 19.53% | |
63 Neutral | kr15.87B | 18.84 | ― | 1.47% | -2.19% | 76.78% | |
58 Neutral | kr2.53B | 15.17 | 7.53% | 2.01% | -4.47% | 6.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SE:AMBEA
Ambea AB
146.60
41.09
38.94%
SE:ATT
Attendo AB
105.30
44.04
71.88%
SE:HUM
Humana AB
48.90
12.05
32.70%
SE:ACAD
AcadeMedia AB
94.40
16.23
20.76%
Ambea AB Corporate Events
Ambea boosts Q1 earnings and expands Nordic care footprint
May 7, 2026
Ambea reported a strong first quarter of 2026, with net sales up 16 per cent to SEK 4,220 million, driven by 4 per cent organic growth and 13 per cent acquired growth, while adjusted EBITA rose 24 per cent to SEK 380 million, lifting the margin to...
Ambea Sets 2026 AGM to Vote on Capital Measures and Incentive Plan
Apr 7, 2026
Ambea AB has issued a corrected notice convening its Annual General Meeting for 12 May 2026 at the company’s head office in Solna, outlining detailed procedures for shareholders to attend in person, vote by proxy or cast advance votes. The c...
Ambea convenes 2026 AGM with proposals on capital structure and board re-election
Apr 7, 2026
Ambea AB has called its Annual General Meeting for 12 May 2026 at the company’s head office in Solna, outlining detailed procedures for shareholders to participate either in person, by proxy or through advance voting. The notice also specifi...
Ambea Publishes 2025 Annual, Quality and Sustainability Report
Mar 31, 2026
Ambea AB has published its 2025 Annual Report, which combines financial statements with a comprehensive Quality Sustainability Report to outline how it aims to future‑proof care in a changing society. The report details the company’s ...
Ambea boosts growth and dividend as Nordic care expansion accelerates
Feb 12, 2026
Care group Ambea reported a strong 2025 with net sales up 13% to SEK 16.0 billion, driven by 4% organic and 10% acquired growth, while maintaining an adjusted EBITA margin of 9.6% and lifting earnings per share by 10%. The board proposed raising t...
Ambea Launches Share Buyback to Optimise Capital Structure
Feb 11, 2026
Ambea AB’s board has approved a new share repurchase programme of up to 2,000,000 shares on Nasdaq Stockholm, to be executed by a mandated credit institution ahead of the 2026 annual general meeting. The initiative is designed to optimise th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.